Trial reportBMC gastroenterology2019
Patient views about the impact of ulcerative colitis and its management with drug treatment and surgery: a nested qualitative study within the CONSTRUCT trial.
Trial report in BMC gastroenterology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- The value of qualitative research in randomized controlled trials involving drugs and medical devices: a systematic mapping review.International journal of technology assessment in health care · 2026Pooled it
- Upadacitinib Induction and Maintenance Therapy Improves Abdominal Pain, Bowel Urgency, and Fatigue in Patients With Ulcerative Colitis: A Post Hoc Analysis of Phase 3 Data.Inflammatory bowel diseases · 2023Trial
- Upadacitinib Treatment Improves Symptoms of Bowel Urgency and Abdominal Pain, and Correlates With Quality of Life Improvements in Patients With Moderate to Severe Ulcerative Colitis.Journal of Crohn's & colitis · 2021Trial
- Beyond the Average: Modeling Individual-Specific Preferences for Ulcerative Colitis Surgery.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2026Article
- Patient experiences in ulcerative colitis: conceptual model and review of patient-reported outcome measures.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2024Review
- Medical consultation in ulcerative colitis: Key elements for improvement.World journal of gastroenterology · 2023Review
- Integrating qualitative interviews in drug development and the use of qualitative evidence in product labelling and health technology assessments: a review.Frontiers in medicine · 2023Review
- Quality of Life in Patients with Acute Severe Ulcerative Colitis: Long-Term Follow-Up Results from the CONSTRUCT Trial.Journal of personalized medicine · 2022Article
- Patient preferences and current practice for adults with steroid-resistant ulcerative colitis: POPSTER mixed-methods study.Health technology assessment (Winchester, England) · 2022Article
- Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1.Gastroenterology & hepatology · 2022Article
- Medication Adherence and Its Influencing Factors Among Inflammatory Bowel Disease Patients in China.International journal of general medicine · 2022Article
- Effect of Shenling Baizhu San on Intestinal Flora in a Rat Model of Ulcerative Colitis with Spleen Deficiency and Dampness.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- What Do Influenza and COVID-19 Represent for Patients With Inflammatory Bowel Disease?Gastroenterology research · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundA nested qualitative interview study within the CONSTRUCT trial was conducted to explore experiences and perceptions of patients with acute severe ulcerative colitis following treatment with infliximab or ciclosporin, surgery, or other medication.
methodsTwo hundred seventy patients with steroid-resistant ulcerative colitis were randomised to either infliximab or ciclosporin. Interviews were conducted with 20 trial participants. Thirty-five data capture events took place in total, 20 interviews conducted 3 months after treatment and a further 15 interviews with the same cohort as second interviews at 12 months.
resultsDisease duration varied but similar stories emerged about how people adjusted to living with ulcerative colitis. Issues raised by patients included; the debilitating effect of the disease on quality of life, living with the unpredictability of symptoms and treatment, dealing with embarrassment and stigma and the desire to share knowledge of the disease with others to combat the private nature of this debilitating illness and bring greater visibility to patient experience of symptoms and outcomes.
conclusionPatients were more positive about treatment with infliximab than ciclosporin, mainly due to the cumbersome intravenous regimen required for ciclosporin. Prompt diagnosis is required and early reporting of changes in symptoms is encouraged to ensure appropriate treatment.
trial registrationThis trial is registered with the ISRCTN registry; number ISRCTN22663589 . The date of registration was 16/05/2008.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.